372 related articles for article (PubMed ID: 10688981)
1. Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats.
Kosasa T; Kuriya Y; Matsui K; Yamanishi Y
Eur J Pharmacol; 2000 Feb; 389(2-3):173-9. PubMed ID: 10688981
[TBL] [Abstract][Full Text] [Related]
2. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats.
Kosasa T; Kuriya Y; Matsui K; Yamanishi Y
Eur J Pharmacol; 1999 Sep; 380(2-3):101-7. PubMed ID: 10513568
[TBL] [Abstract][Full Text] [Related]
3. Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats.
Kosasa T; Kuriya Y; Yamanishi Y
Jpn J Pharmacol; 1999 Oct; 81(2):216-22. PubMed ID: 10591480
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats.
Kosasa T; Kuriya Y; Matsui K; Yamanishi Y
Eur J Pharmacol; 1999 Dec; 386(1):7-13. PubMed ID: 10611458
[TBL] [Abstract][Full Text] [Related]
5. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Ogura H; Kosasa T; Kuriya Y; Yamanishi Y
Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):609-13. PubMed ID: 11256231
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Jann MW; Shirley KL; Small GW
Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
[TBL] [Abstract][Full Text] [Related]
7. Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate-induced central and peripheral cholinergically mediated responses in the rat.
Dronfield S; Egan K; Marsden CA; Green AR
J Psychopharmacol; 2000; 14(3):275-9. PubMed ID: 11106308
[TBL] [Abstract][Full Text] [Related]
8. Central and peripheral activity of cholinesterase inhibitors as revealed by yawning and fasciculation in rats.
Ogura H; Kosasa T; Kuriya Y; Yamanishi Y
Eur J Pharmacol; 2001 Mar; 415(2-3):157-64. PubMed ID: 11274994
[TBL] [Abstract][Full Text] [Related]
9. Effect of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate, a novel acetylcholinesterase inhibitor, on spatial cognitive impairment induced by chronic cerebral hypoperfusion in rats.
Xu AJ; Chen Z; Yanai K; Huang YW; Wei EQ
Neurosci Lett; 2002 Oct; 331(1):33-6. PubMed ID: 12359317
[TBL] [Abstract][Full Text] [Related]
10. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities.
Cheng DH; Tang XC
Pharmacol Biochem Behav; 1998 Jun; 60(2):377-86. PubMed ID: 9632220
[TBL] [Abstract][Full Text] [Related]
11. Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine.
Zhao Q; Tang XC
Eur J Pharmacol; 2002 Nov; 455(2-3):101-7. PubMed ID: 12445575
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of orally active cholinesterase inhibitory activity of Prunus persica L. Batsch in rats.
Suh SJ; Koo BS; Jin UH; Hwang MJ; Lee IS; Kim CH
J Mol Neurosci; 2006; 29(2):101-7. PubMed ID: 16954599
[TBL] [Abstract][Full Text] [Related]
13. Neurochemical effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-b enzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, in rats.
Hirai K; Kato K; Nakayama T; Hayako H; Ishihara Y; Goto G; Miyamoto M
J Pharmacol Exp Ther; 1997 Mar; 280(3):1261-9. PubMed ID: 9067312
[TBL] [Abstract][Full Text] [Related]
14. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats.
Liang YQ; Tang XC
Neurosci Lett; 2004 May; 361(1-3):56-9. PubMed ID: 15135892
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease.
Crismon ML
Pharmacotherapy; 1998; 18(2 Pt 2):47-54; discussion 79-82. PubMed ID: 9543465
[TBL] [Abstract][Full Text] [Related]
17. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Rakonczay Z
Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
[TBL] [Abstract][Full Text] [Related]
18. Effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1 -H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, on impaired learning and memory in animal models.
Miyamoto M; Takahashi H; Kato K; Hirai K; Ishihara Y; Goto G
J Pharmacol Exp Ther; 1996 Jun; 277(3):1292-304. PubMed ID: 8667190
[TBL] [Abstract][Full Text] [Related]
19. Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats--Is there a potential for Alzheimer's disease treatment?
Misik J; Korabecny J; Nepovimova E; Kracmarova A; Kassa J
Neurosci Lett; 2016 Jan; 612():261-268. PubMed ID: 26708634
[TBL] [Abstract][Full Text] [Related]
20. Effect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats.
Hatip-Al-Khatib I; Iwasaki K; Yoshimitsu Y; Arai T; Egashira N; Mishima K; Ikeda T; Fujiwara M
Br J Pharmacol; 2005 Aug; 145(8):1035-44. PubMed ID: 15951830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
